Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of inhaled LAM-001 in lymphangioleiomyomatosis
NL-OMON48177Phase 1Completed
- Sponsor
- AI Therapeutics
- Start
- Dec 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LAM-001 in lymphangioleiomyomatosis (LAM), sponsored by AI Therapeutics. Primary endpoints: Safety and tolerability over 14 days, Longer-term safety and tolerability up to 12 weeks and 3 more. Started Dec 2018; status: completed.
02
Drugs
LAM-001
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NL-OMON48177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48177.